Metastatic Neoplasm clinical trials at UCSF
1 in progress, 1 open to new patients
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
open to eligible people ages 18 years and up
The purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression free survival and overall survival than patients treated with trastuzumab plus chemotherapy.
San Francisco, California and other locations